CD19 chimeric antigen receptor T cell therapy - Takara Bio

Drug Profile

CD19 chimeric antigen receptor T cell therapy - Takara Bio

Alternative Names: CD19-CAR gene therapy - Takara Bio; CD19-CAR T cell therapy - Takara Bio; TBI-1501

Latest Information Update: 29 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Jichi Medical School; Takara Bio
  • Class Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma

Most Recent Events

  • 19 May 2017 Takara Bio plans a phase I/II trial for Acute lymphoblastic leukaemia (Second-line therapy or greater) in Japan (NCT03155191)
  • 29 Dec 2016 CD19 Chimeric Antigen Receptor T cell therapy is still in phase I/II trials for Non-Hodgkin's lymphoma (Second-line therapy or greater) in Japan (IV)
  • 01 May 2014 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in Japan (IV) (NCT02134262)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top